Hemophagocytic Lymphohistiocytosis After Lung Transplant: Report of 2 Cases and a Literature Review

Enrique Diaz-Guzman,1 Bei Dong,1 Stephen B. Hobbs,2 Melissa V. Kesler,3 Don Hayes, Jr.1, 4

Abstract

Hemophagocytic lymphohistiocytosis is a rare and often fatal disease that may occur in solid organ transplant recipients. Here, we describe 2 patients who developed hemophagocytic lymphohistiocytosis after having a lung transplant and present a review of all cases of hemophagocytic lymphohistiocytosis occurring in solid organ transplant recipients. Diagnosis of hemophagocytic lymphohistiocytosis relies on the association of clinical findings and the presence of hemophagocytosis. Clinical presentation is nonspecific and patients may present with unexplained sepsis or multiple organ failure. Management consists of treating the underlying process; but unfortunately, the prognosis is poor.

Key words: Pancytopenia, Ferritin, Transplantation, Histiocyte

Introduction

Hemophagocytic lymphohistiocytosis (HLH), also known as hemophagocytic syndrome, is a distinct clinical entity, characterized by a systemic proliferation of hemophagocytic cells resulting in multisystemic inflammation.1 The term HLH (also known as Familial Hemophagocytic Lymphohistiocytosis) also has been used by the International Histiocyte Society to describe an autosomal recessive defect in young children, caused by several genetic mutations that alter the regulation of a normal immune response to external stimuli.2-4 An acquired form of HLH (also known as secondary or reactive HLH), is described in association with severe sepsis, autoimmune disorders, malignancy, immune-compromised states, infections, and solid organ transplant.5,6

Hemophagocytic lymphohistiocytosis is characterized by the presence of prolonged fever (> 7 days), pancytopenia, and splenomegaly. Additional findings may include generalized rash, neurologic symptoms, and systemic lymphadenopathy. Diagnosis of the disease is supported by the certain laboratory abnormalities (cytopenia in at least 2 cell lines, hypertriglyceridemia, hypofibrinogenemia, low or absent natural killer cell activity, elevated ferritin level, and high soluble CD 25 level).5 Unfortunately, clinical and laboratory findings are nonspecific and may be difficult to distinguish from those of the underlying disease. The presence of hemophagocytosis (activated macrophages engulf different types of blood cells) is considered diagnostic; nevertheless, this phenomenon may be absent early on, during the disease.7

Diagnosis of HLH is one of exclusion, and recognition is frequently delayed because the condition mimics other, more-common diseases. Although HLH has been described previously as complicating liver and kidney transplant, to our knowledge, it has not been reported in association with lung transplant. Hemophagocytic lymphohistiocytosis is uncommon, and the clinician’s familiarity with its clinical features and diagnostic criteria is imperative for establishing a prompt diagnosis.

It is in that context, that we present 2 patients who developed HLH after lung transplant. In addition, we summarize the available literature regarding HLH occurring after solid organ transplantation.
Case 1
A 27-year-old woman with cystic fibrosis presented to the hospital 5 months after having a bilateral lung transplant with altered mental status and fever. Her physical examination revealed lethargy, jaundice, and hepatosplenomegaly. Her admission laboratory work up revealed pancytopenia with a white blood cell count of $1.3 \times 10^9$/L, hemoglobin of 86 g/L, and platelet count of $109 \times 10^9$/L. Additional laboratory findings consisted of aspartate transaminase, 136 U/L; aspartate transaminase, 48 U/L; alkaline phosphatase, 711 U/L; gamma glutamyl transpeptidase, 354 U/L; total bilirubin, 259.9 µmol/L; conjugated bilirubin, 25 µmol/L; ammonia, 108 µmol/L; and lactate dehydrogenase, 653 U/L. Coagulation times were normal: activated partial thromboplastin time, 23 seconds; prothrombin time, 9.7 seconds; and international normalized ratio (for blood clotting time), 0.9. Clottable fibrinogen was 9.9 µmol/L. An abdominal ultrasound demonstrated sludge within the gallbladder, with mild gallbladder wall thickening, and poor visualizing of the spleen. Hepatitis serology including hepatitis B surface antigen and core IgM antibody, hepatitis C antibody, and hepatitis A IgM antibody were negative.

Within days of admission, her mental status declined requiring initiation of mechanical ventilation. The patient remained febrile during her hospital course (> 7 days) and eventually became hemodynamically unstable and developed a shock state requiring multiple vasopressor agents. A magnetic resonance image of the brain (Figure 1) demonstrated areas of subcortical T2 signal abnormality involving the posterior temporal, parietal, and occipital lobes. Cerebral spinal fluid analysis revealed clear, colorless fluid with 2 red blood cells/µL and no white blood cell count, with an elevated glucose of 6.27 mmol/L, and protein of 6.2 g/L. Cerebral spinal fluid cultures, blood cultures, and urine cultures were negative for bacterial, acid-fast bacteria, fungal, and viral infections. Cerebral spinal fluid was also negative for Epstein-Barr virus DNA, enterovirus RNA, JC virus DNA, varicella-zoster virus DNA, West Nile virus DNA, and herpes simplex virus DNA. Further blood work-up included Epstein-Barr virus, parvovirus B19, herpes simplex virus, human herpesvirus 6, human herpesvirus 8, and cytomegalovirus, all negative by polymerase chain reaction analysis for DNA. An electroencephalogram was performed, finding multifocal and independent epileptiform discharges independently over both hemispheres with moderate bihemispheric slow-wave activity.

A liver biopsy was done that revealed a hepatic parenchyma with normal lobular architecture and marked cholestasis with no evidence of fibrosis. Immunohistochemical stains were negative, and no viral inclusions or granulomas were present. Bacterial, viral, and fungal cultures on the liver tissue were negative.

Approximately 2 weeks after hospitalization, a diagnosis of HLH was considered. Additional testing to rule out HLH included a ferritin level of 8893.6 pmol/L, and a triglyceride level of 2.75 mmol/L. Bone marrow biopsy demonstrated a hypocellular bone marrow with trilineage maturation; relative erythroid predominance, with no increase in blasts; and no evidence of infectious or malignant processes; however, the macrophages included hemosiderin-laden forms with increased hemophagocytosis (Figure 2). Bacterial, acid-fast bacteria, viral, and fungal cultures were all negative. The patient deteriorated, despite support with

Figure 1. Subcortical T2 signal abnormality involving the posterior temporal, parietal and occipital lobes.

Figure 2. Bone marrow aspirate (1000 × oil) showing 2 hemophagocytic histiocytes. The solid arrow indicates an engulfed mature red blood cell; the dashed arrow shows a degenerating phagocytosed nucleus.
mechanical ventilation, and died as a result of multiorgan dysfunction approximately 30 days after admission.

**Case 2**

A 65-year-old woman with history of end-stage chronic obstructive pulmonary disease, presented to the hospital approximately 4 months after undergoing a single left lung transplant. The patient complained of intermittent symptoms of altered mental status, headache, tremors, low-grade fever, and weight loss over the course of several weeks. She underwent a bronchoscopy to rule out acute rejection (which was complicated with development of pneumothorax and respiratory failure). Biopsies showed no evidence of acute cellular rejection.

A computed tomography of the chest showed no evidence of pneumonia or pleural effusions, and a computed tomography of the abdomen revealed the presence of splenomegaly. The patient was intubated and transferred to the intensive care unit, where she developed fever and shock within 48 hours of admission requiring supportive care with vasopressor agents and treatment with broad spectrum antibiotics. A diagnosis of septic shock was considered.

Her admission laboratory work up revealed: white blood cell count, $6.8 \times 10^9$/L; hemoglobin, 91 g/L; and platelet count, $93 \times 10^9$/L; aspartate transaminase, 70 U/L; aspartate transaminase, 50 U/L; alkaline phosphatase, 540 U/L; total bilirubin, 70.1 µmol/L; conjugated bilirubin, 59.8 µmol/L; lactate dehydrogenase, 570 U/L; and haptoglobin 1 µmol/L. The coagulation times were (all normal) as follows: activated partial thromboplastin time, 26 seconds; prothrombin time, 11 seconds; and international normalized ratio, 1.1. Clottable fibrinogen was 12.3 µmol/L. Antibodies for HLH syndrome were negative. Blood cultures for bacterial and fungal organisms were negative. Over the next 7 days, the patient developed pancytopenia and became less reactive to verbal or painful stimuli. A computed tomography of the brain showed new, bilateral, hypodense lesions involving the cerebral hemispheres, consistent with infarction.

A further diagnostic work-up showed an Epstein-Barr virus DNA by polymerase chain reaction in peripheral blood of 5000 DNA copies/mL, and an elevated ferritin level of 2195.3 pmol/L. Additionally, a natural killer cell assay showed decreased natural killer cell function. Bone marrow biopsy demonstrated hypocellular bone marrow (trilineage hypoplasia) without evidence of hematolymphoid malignancy or hemophagocytosis. A diagnosis of secondary HLH was based on clinical and laboratory findings, and the patient was treated with intravenous acyclovir. Despite supportive therapy, the patient deteriorated and died approximately 1 month after hospital admission.

**Discussion**

Hemophagocytic lymphohistiocytosis, also known as hemophagocytic syndrome, is a rare, potentially life-threatening condition, characterized by hemophagocytosis presence in the bone marrow and other tissues, manifested clinically with multisystemic inflammation. Hemophagocytic lymphohistiocytosis was probably first described by Scott and Robb-Smith in 1939, as a syndrome characterized by fever, peripheral lymph node enlargement, pancytopenia, and histiocytic proliferation. Nevertheless, Farquhar and Claire are credited with the first report of HLH, which they named familial hemophagocytic reticulosis. The first series of transplant patients affected with HLH were described by Tisdall and associates, in 1979, who reported HLH associated with viral infections in 19 patients (including 13 kidney transplant recipients).

Although the clinical features of HLH have been well described, the pathophysiology of the disease is not completely understood. Genetic studies in patients with primary HLH have revealed mutations that affect the intracellular trafficking and delivery to target cells of cytotoxic granules necessary for apoptosis. Mutations affecting perforin (a cytotoxic protein), Munk 13-4 (involved in granule exocytosis), and syntaxin 11 (involved in intracellular trafficking) have been described in association with familial HLH. In addition, genetic syndromes with a propensity of developing HLH include Griscelli syndrome, in which there are mutations of Rab27a (necessary for docking secretory granules at the cell membrane) and Chediak-Higashi syndrome, which is caused by mutations in the lysosomal trafficking regulator protein. In comparison, the pathophysiology of secondary HLH appears to be linked to certain triggering events that cause abnormal macrophage activation and T-cell proliferation.
Secondary or reactive HLH may develop at any age, and frequently is associated with systemic infection (Table 1), immunodeficiency, malignancy, and inflammatory or autoimmune disorders. No underlying cause is identified in approximately 20% of the patients. To the best of our knowledge, these are the first reported cases of HLH occurring after a lung transplant. Both cases occurred within 6 months of the transplant. In our review of the literature, we found that HLH may develop as early as a few weeks after transplant, although the majority occurs several months after transplant (Table 2). No cause was found in the first case, and Epstein-Barr virus was implicated as the causative agent in the second one. Our review of the literature found 67 instances of reactive HLH reported after solid organ transplant: 60 in kidney transplant recipients, 5 instances in liver transplant recipients, and 2 instances in heart transplant recipients. Most instances were associated with viral infection, among which cytomegalovirus appears the most-frequent causative pathogen (20 of 67 instances). Epstein-Barr virus infection accounted for only 7 cases, although it has been described as the most-common triggering agent in other series of patients with HLH. Human herpes viruses, including herpes simplex virus 5 and human herpesvirus 8, were also associated with 7 instances of HLH.

The clinical presentation of HLH is characterized by prolonged fever (> 7 days) and hepatosplenomegalgy. A previous review of the literature suggests that fever is a universal finding, and constitutional symptoms such as weakness, fatigue, anorexia, weight loss are present in only 30% of patients. Physical findings include lymphadenopathy, hepatomegaly, splenomegaly, and skin rash. Other reports suggest that symptoms of central nervous function dysfunction are found in more than 50% of the patients. Sometimes, profound neurologic symptoms such as seizures, irritability, cranial nerve palsies, altered consciousness, and ataxia are found. A recent report suggests that patients with HLH present with findings of foci of inflammation, detected by magnetic resonance imaging scanning. These findings include multiple nodular or ring-enhancing parenchymal lesions, parenchymal lesion on T2-weighted images or confluent parenchymal lesions, leptomeningeal enhancement mild ventriculomegaly, and brain edema.

### Table 1. Infections associated with hemophagocytic lymphohistiocytosis.

<table>
<thead>
<tr>
<th>Category</th>
<th>Infection associated with hemophagocytic lymphohistiocytosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Viral</td>
<td>Herpes simplex virus, varicella zoster virus, Cytomegalovirus, Epstein-Barr virus, human herpesvirus 6, human herpesvirus 8</td>
</tr>
<tr>
<td>Bacterial</td>
<td>Enteric gram negative rods, Streptococcus pneumoniae, <em>Staphylococcus</em>, <em>Brucella</em>, <em>Babesia</em>, <em>Mycoplasma</em>, <em>Rickettsia</em>, <em>mycobacteria</em> fungi</td>
</tr>
<tr>
<td>Parasitic</td>
<td>Histoplasmosis, Cryptococcus, candida</td>
</tr>
</tbody>
</table>

### Table 2. Diagnostic guidelines for hemophagocytic lymphohistiocytosis.

<table>
<thead>
<tr>
<th>Diagnosis of hemophagocytic lymphohistiocytosis is done by fulfilling 1 of the following criteria:</th>
</tr>
</thead>
<tbody>
<tr>
<td>(1) A molecular diagnosis consistent with hemophagocytic lymphohistiocytosis (eg, PRF mutations, SAP mutations, MUNC13-4 mutations)</td>
</tr>
<tr>
<td>OR</td>
</tr>
<tr>
<td>(2) Five out of 8 of the following are required</td>
</tr>
<tr>
<td>Fever</td>
</tr>
<tr>
<td>Splenomegaly</td>
</tr>
<tr>
<td>Cytopenia (affecting more than 2 cell lineages, hemoglobin ≤ 9 g/dL, ( &lt; 100,000 \text{ platelets per} \mu\text{L} ), ( &lt; 1000 \text{ neutrophils per} \mu\text{L} ))</td>
</tr>
<tr>
<td>Hypertriacyleridemia (triglycerides ≥ 265 mg/dL) and/or hypofibrinogenemia (fibrinogen ≤ 150 mg/dL)</td>
</tr>
<tr>
<td>Hemophagocytosis in the bone marrow, spleen, or lymph nodes without evidence of malignancy</td>
</tr>
<tr>
<td>Low or absent natural killer–cell cytotoxicity</td>
</tr>
<tr>
<td>Hyperferritinemia (ferritin ≥ 500 ng/mL)</td>
</tr>
<tr>
<td>Elevated soluble CD25 (interleukin-2 receptor, a reflection of hyper-</td>
</tr>
<tr>
<td>tyrosinemia)</td>
</tr>
</tbody>
</table>

**Abbreviations:** PRF, pulse repetition frequency; SAP, serum alkaline phosphatase

The diagnosis of HLH is based on clinical and laboratory features, which are nonspecific and sometimes difficult to differentiate from underlying disorders or common causes of multiorgan inflammation, such as sepsis syndrome. Similarly, the 2 patients in this report presented with altered mental status, fever, and hepatosplenomegaly. Owing to the nonspecific nature of symptoms, diagnosis of HLH was not suspected until weeks after hospital admission. The criteria for establishing a diagnosis of HLH is shown in Table 3. With the discovery that defective natural killer cell function is integral to the development of HLH, demonstration of decreased natural killer cell activity (measurable by flow cytometry) has been added as a new diagnostic criterion, as has elevated serum soluble CD25 (IL-2 receptor, a reflection of hyper-tyrosinemia). Finally, a molecular genetic abnormality consistent with HLH (eg, perforin or Munc13-4 mutations) is considered diagnostic.
Hemophagocytic lymphohistiocytosis is associated with a poor prognosis; the mortality rate from HLH ranges from 22% to 59%.\textsuperscript{13} Mortality appears to be particularly high among solid organ transplant recipients, and our literature review suggests a mortality rate of 52%. Hematologic malignancy or Epstein-Barr virus infection is associated with the worse prognosis, while bacterial and fungal infections appear to be associated with a better prognosis. Treatment of secondary HLH is mainly supportive and involves treating the underlying cause, whereas in patients without underlying systemic diseases, etoposide combined with corticosteroid therapy has been reported as being successful.\textsuperscript{14}

In conclusion, HLH is an uncommon but potentially lethal complication that may develop in solid organ transplant patients, including lung transplant recipients. The diagnosis should be considered in patients that develop clinical features consistent with a sepsislike syndrome or multiple organ failure of unclear cause, which presents with the appropriate constellation of laboratory abnormalities. Bone marrow biopsy and natural killer cell activity testing should be obtained in such cases, and consultation with a hematology-oncology specialist should be considered. Treatment of HLH is complex and is dictated by the presence or absence of underlying conditions. Despite its treatment, the prognosis remains poor.

\textbf{References}


\begin{table}[h]
\centering
\caption{Reported cases of hemophagocytic lymphohistiocytosis in solid organ transplant recipients.}
\begin{tabular}{llllll}
\hline
Transplanted organ & Reference & Patient No. & Time of onset after transplant (mo) & Cause & Prognosis \\
\hline
Kidney & Karras et al (15) & 1-17 & 0.5-181 & EBV (n=3), CMV (n=3), HHV6, HHV8, HCV, TB (n=2), Toxoplasmosis, \textit{Bartonella}, lymphoma, unknown (n=2), Pneumocystis & D (n=8), S (n=9) \\
Kidney & Tisdall et al (16) & 18-30 & 0.5-22 & CMV (n=9), HSV, VZV, EBV & D (n=4), S (n=8) \\
Kidney & Reiner and Spivak (5) & 31-32 & 18-108 & Histoplasmosis, CMV & S (n=1), D (n=1) \\
Kidney & Kursat et al (17) & 33-36 & 24-25 & HHV8, TB, unknown (n=2) & D (n=4) \\
Kidney & Rostaing (18) & 37-42 & 1-8 & CMV (n=2), Toxoplasmosis (n=2), T-cell lymphoma & D (n=3), S (n=2) \\
Kidney & Slovut et al (19) & 43 & 216 & Babesiosis & S \\
Kidney & Peeters et al (20) & 44 & 15 & T-cell lymphoma & D \\
Kidney & Boehler et al (21) & 45-46 & 36-72 & CMV (n=2) & D (n=2) \\
Kidney & Kaplan et al (22) & 47 & 60 & T lymphoma & D \\
Kidney & Broeckart-Van Dechoven (23) & 48 & 15 & Lymphosarcoma & D \\
Kidney & Dru and Dru (24) & 49 & 12 & Kaposis sarcoma & D \\
Kidney & Dargent et al (25) & 50 & 36 & Angiosarcoma & D \\
Kidney & Rossi et al (26) & 51 & 1 & HHV6 & D \\
Kidney & Luppi et al (27) & 52 & 5 & HHV8 & S \\
Kidney & Gurkan et al (28) & 53-56 & 0.9-2 & EBV (n=1), CMV (n=2), unknown (n=1) & D (n=3), S (n=1) \\
Kidney & Gonzalez-Porada (29) & 57 & 0.9 & Canula glabra & S \\
Kidney & Ardalan et al (30) & 58 & 24 & Parovirus B19 & S \\
Kidney & Lo et al (31) & 59-60 & 15-60 & Histoplasmosis (n=2) & S (n=2) \\
Liver & George et al (32) & 61 & 72 & EBV & S \\
Liver & Takeshita et al (33) & 62-63 & 0.5-4 & EBV, B lymphoma & D (n=2) \\
Liver & Dharancy et al (34) & 64 & 0.5 & HHV6 & D \\
Liver & Leconte et al (35) & 65 & 1 & HHV6 & S \\
Heart & Masri et al (36) & 66 & 8 & Lymphosarcoma & S \\
Heart & Pucci et al (37) & 67 & 1 & CMV & D \\
Lung & Diaz-Guzman et al (Current report) & 68-69 & 4-5 & EBV, unknown & D \\
\hline
\end{tabular}


